Drug Profile
Research programme: antibody drug conjugates - Esperance Pharmaceuticals
Alternative Names: EP 400 series; EP-400 - Esperance PharmaceuticalsLatest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Esperance Pharmaceuticals
- Class Antineoplastics; Immunoconjugates
- Mechanism of Action Cell death stimulants; Cell membrane permeability enhancers; Cell membrane structure modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 28 Jun 2021 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 11 May 2017 Preclinical trials in Haematological malignancies in USA (Parenteral) before May 2017 (Esperance Pharmaceuticals pipeline, May 2017)